Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 5,100 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 5,100 shares of the firm’s stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $56.00, for a total value of $285,600.00. Following the completion of the sale, the insider now directly owns 256,580 shares of the company’s stock, valued at approximately $14,368,480. The trade was a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hims & Hers Health Trading Up 0.8%

Hims & Hers Health stock traded up $0.47 during midday trading on Monday, reaching $56.80. The company’s stock had a trading volume of 27,421,918 shares, compared to its average volume of 20,753,918. The stock has a market cap of $12.71 billion, a PE ratio of 129.09 and a beta of 2.09. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The business has a 50-day moving average price of $42.23 and a 200-day moving average price of $37.33.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the business posted $0.05 earnings per share. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 29th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Needham & Company LLC raised their price target on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $38.00.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Yousif Capital Management LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $1,788,000. State of Alaska Department of Revenue bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $2,628,000. Kestra Private Wealth Services LLC increased its stake in shares of Hims & Hers Health by 105.1% in the fourth quarter. Kestra Private Wealth Services LLC now owns 29,106 shares of the company’s stock valued at $704,000 after buying an additional 14,912 shares during the period. Louisiana State Employees Retirement System acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $2,234,000. Finally, New York State Teachers Retirement System raised its position in shares of Hims & Hers Health by 3,284.6% during the fourth quarter. New York State Teachers Retirement System now owns 99,812 shares of the company’s stock worth $2,413,000 after acquiring an additional 96,863 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.